ライフサイエンスコーパス: postherpetic

1 The most recognized are postherpetic itch, brachioradial pruritus, trigeminal tr

2 cluding graft-associated neovascularization, postherpetic keratitis scarring, lipid keratopathy, and

3 nce rate ratio 0.67 [0.61-0.74]) and 38% for postherpetic neuralgia (0.62 [0.50-0.79]).

4 2 among placebo recipients) and 107 cases of postherpetic neuralgia (27 among vaccine recipients and

5 Herpes zoster (HZ) and postherpetic neuralgia (PHN) cause significant morbidity

6 The limitations of current treatments for postherpetic neuralgia (PHN) have led to the investigati

7 Postherpetic neuralgia (PHN) is a common complication of

8 Postherpetic neuralgia (PHN) is a syndrome of often intr

9 t is evident that zoster vaccination reduces postherpetic neuralgia (PHN) risk by reducing herpes zos

10 modeling differences in antiviral efficacy, postherpetic neuralgia (PHN) risk, and other illness par

11 quence of viral reactivation are at risk for postherpetic neuralgia (PHN), a painful and long-lasting

12 zoster (HZ) burden of illness, incidence of postherpetic neuralgia (PHN), and incidence of HZ were a

13 urden associated with herpes zoster (HZ) and postherpetic neuralgia (PHN), intentions for recommendin

14 s chronic and often debilitating pain called postherpetic neuralgia (PHN), which can last for months

15 les risk developing the painful condition of postherpetic neuralgia (PHN), which has been difficult t

16 of famciclovir treatment on the duration of postherpetic neuralgia (PHN), which was defined as pain

17 1 million U.S. adults, many of whom develop postherpetic neuralgia (PHN).

18 suffering due to acute and chronic pain, or postherpetic neuralgia (PHN).

19 alyzed, including ophthalmic zoster (OZ) and postherpetic neuralgia (PHN).

20 ad a history of zoster (group 1), zoster and postherpetic neuralgia (PHN; group 2), or no history of

21 rom 18 subjects with and 16 subjects without postherpetic neuralgia after unilateral shingles.

22 of herpes zoster and 3300 fewer episodes of postherpetic neuralgia among 5.5 million eligible indivi

23 dly reduced morbidity from herpes zoster and postherpetic neuralgia among older adults.

24 ence, severity, or both of herpes zoster and postherpetic neuralgia among older adults.

25 In postherpetic neuralgia and complex regional pain syndrom

26 percent (P<0.001), reduced the incidence of postherpetic neuralgia by 66.5 percent (P<0.001), and re

27 mg twice daily) provides superior relief of postherpetic neuralgia compared with placebo at the end

28 In treating diabetic neuropathy and postherpetic neuralgia compared with placebo, gabapentin

29 coverage and incidence of herpes zoster and postherpetic neuralgia consultations.

30 ence rate ratio 0.65 [95% 0.60-0.72]) and of postherpetic neuralgia fell by 50% (0.50 [0.38-0.67]).

31 Patients were aged 18-90 years, had had postherpetic neuralgia for at least 6 months, and had an

32 The group with postherpetic neuralgia had a mean density of 339 +/- 97

33 history, and treatment of herpes zoster and postherpetic neuralgia in immunocompetent older adults a

34 is effective in preventing herpes zoster and postherpetic neuralgia in immunocompetent older adults.

35 programme on incidence of herpes zoster and postherpetic neuralgia in this population.

36 incidence and severity of herpes zoster and postherpetic neuralgia increase with age in association

37 Postherpetic neuralgia is not prevented by early systemi

38 ients aged 60-89 years for herpes zoster and postherpetic neuralgia occurring between Oct 1, 2005, an

39 we enrolled patients (aged 22-89 years) with postherpetic neuralgia of at least 6 months' duration fr

40 Patients with postherpetic neuralgia often have an increased sensitivi

41 Thus, the pathophysiology of postherpetic neuralgia pain may involve a new bilateral

42 Shingles can cause chronic neuropathic pain (postherpetic neuralgia) long after skin lesions heal.

43 ered and consultations for herpes zoster and postherpetic neuralgia, and aggregated these data to est

44 Existing treatments for postherpetic neuralgia, and for neuropathic pain in gene

45 (BOI), from 66.5% to 35.4% for incidence of postherpetic neuralgia, and from 51.3% to 21.1% for inci

46 been implicated in the painful condition of postherpetic neuralgia, is regulated by the cytoplasmic

47 sults in zoster, which may be complicated by postherpetic neuralgia, myelitis, meningoencephalitis, a

48 s herpes zoster, which may be complicated by postherpetic neuralgia.

49 apeutic potential of EMA401 in patients with postherpetic neuralgia.

50 cause zoster, which is often complicated by postherpetic neuralgia.

51 62% against herpes zoster and 70-88% against postherpetic neuralgia.

52 with increased HZ severity and occurrence of postherpetic neuralgia.

53 s exposure and can be further complicated by postherpetic neuralgia.

54 associated with reduced HZ severity and less postherpetic neuralgia.

55 d and sustained pain relief in patients with postherpetic neuralgia.

56 tects older adults against herpes zoster and postherpetic neuralgia.

57 g the subjective pain score in patients with postherpetic neuralgia.

58 ve tactile allodynia in this animal model of postherpetic neuralgia.

59 The secondary end point was the incidence of postherpetic neuralgia.

60 ich resemble the unique clinical features of postherpetic neuralgia.

61 ew insights into the potential mechanisms of postherpetic neuralgia.

62 dividuals most at risk of prolonged pain and postherpetic neuralgia.

63 there was very little pain, and there was no postherpetic neuralgia.

64 causative agent of chickenpox, shingles, and postherpetic neuralgia.

65 A postherpetic-neuralgia patient abruptly discontinued pre